This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here's Why

Core Insights - Palisades Investment Partners has completely exited its position in ADMA Biologics, selling 398,647 shares for approximately $7.3 million, indicating a strategic shift in investment focus [1][2][7] Company Overview - ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapeutics aimed at treating immune deficiencies and infectious diseases [6][9] - The company reported a total revenue of $474.2 million and a net income of $208.9 million for the trailing twelve months (TTM) [4] Financial Performance - ADMA Biologics experienced a year-over-year revenue growth of 14%, reaching $122 million, alongside a 7% increase in GAAP net income [8] - The stock price of ADMA Biologics closed at $15.48, reflecting a 5% decline over the past year, which is significantly lower than the S&P 500's 19% gain during the same period [3][4] Investment Strategy - Palisades' exit from ADMA Biologics highlights its adherence to a small-cap momentum strategy, where investments are sold when financial or operational momentum appears to stall [7][10] - The fund's decision to liquidate its position, despite ADMA's revenue and earnings growth, suggests a cautious outlook on the stock's future appreciation potential [10]